Contact Us |

Search 

עברית  

    logoemp

 

slogN

 

dayanews emp nodaya

 21 | April | 2016

Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke

Read more >


 13 | April | 2016

Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents

Read more >


 16 | February | 2016

National Institutes of Health’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

Read more >


 10 | February | 2016

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update

Read more >


 26 | January | 2016

Pluristem to Present at Bio CEO & Investor Conference in New York City on February 8, 2016

Read more >


 12 | January | 2016

Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant

Read more >

 
 
 
 

From the CEO

 

Our vision at Pluristem Therapeutics is to leverage our position as a global leader in placenta-based cell science to develop and manufacture safe and effective cell therapy products. We believe our cutting edge technology can produce therapies that will help people affected by inflammation, ischemia, hematological disorders, and acute radiation syndrome, and establish us as a leading company in the cell therapy arena. We also believe that in cell therapy “the process is the product”, and precise control of the entire process, from obtaining cells from the source, to delivery to the patient, is vital to the success of a cell therapy. Our fully automated process, proprietary 3D cell expansion technology and increasing knowledge of the placental cell drive us to continue developing additional candidates for our product portfolio.

 

 

Recently we have made significant progress in the execution of our strategy to shorten the time to commercialization of our PLX cells.

The PLX cell program in critical limb ischemia has been selected for the European Medicines Agency’s Adaptive Pathways pilot project, which potentially allows for early marketing authorization of a therapy in a restricted patient population, and the possibility of later approval for use in broader patient populations. In Japan, we have applied to the Accelerated Pathway for Regenerative Medicine for  our PLX cells in critical limb ischemia. Japan’s Pharmaceuticals and Medical Devices Agency just validated the proposed quality and  large-scale manufacturing methods for PLX-PAD cells for use in clinical trials there. We are hopeful that these rapid pathways will allow us to shorten the time it will take to bring our advanced cell therapies to patients in need of innovative treatments.

 

Zami Aberman
Chairman and CEO

 

 

 

 

 

 

Japanese Ambassador visit Pluristem, March 2016

DSC 8327

 

 

 

Pluristem Corporate Presentation, April 2016

Print PDF >Click Here

 

dec2015 01  
   

t f link y r m p

 

 

The content, text, graphics, data, and services offered herein (the "Content") are provided solely to educate users of this web site on Pluristem and the goods and/or services it provides.  Nothing in the Content should be considered, or used as a substitute for, medical advice, diagnosis or treatment.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.  Reliance on the Content or any portion thereof, or other visitors to the web site, is solely at your own risk.